参考文献/References:
[1] Jelinic M,Leo CH,Post UE,et al. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment[J]. FASEB J,2014,28(1):275-287.
[2] Ferreira VM,Gomes TS,Reis LA,et al. Receptor-induced dilatation in the systemic and intrarenal adaptation to pregnancy in rats[J]. PLoS One,2009,4(3):e4845.
[3] Valkovic AL, Leckey MB, Whitehead AR, et al. Real-time examination of cAMP activity at relaxin family peptide receptors using a BRET-based biosensor[J]. Pharmacol Res Perspect,2018,6(5):e432.
[4] Leo CH, Jelinic M, Ng HH, et al. Serelaxin: a novel therapeutic for vascular diseases[J]. Trends Pharmacol Sci,2016,37(6):498-507.
[5] Mcguane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide[J]. Endocrinology,2011,152(7):2786-2796.
[6] Fernandez-Patron C,Radomski MW,Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor[J]. Circ Res,1999,85(10):906-911.
[7] Wang D, Luo Y, Myakala K, et al. Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats[J]. Sci Rep,2017,7(1):9793.
[8] Ponikowski P,Mitrovic V,Ruda M,et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure[J]. Eur Heart J,2014,35(7):431-441.
[9] Schiffner R,Nistor M,Bischoff SJ,et al. Effects of human relaxin-2(serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model[J]. Hypoxia (Auckl),2018,6:11-22.
[10] Dschietzig T,Bartsch C,Richter C,et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist:attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB[J]. Circ Res,2003,92(1):32-40.
[11] Bitto A, Irrera N, Minutoli L, et al. Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice[J]. Clin Sci (Lond),2013,125(12):575-585.
[12] Debrah DO,Debrah JE,Haney JL,et al. Relaxin regulates vascular wall remodeling and passive mechanical properties in mice[J]. J Appl Physiol (1985),2011,111(1):260-271.
[13] Xu Q,Chakravorty A,Bathgate RA,et al. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats[J]. Hypertension,2010,55(5):1260-1266.
[14] Chan SL,Sweet JG,Cipolla MJ. Treatment for cerebral small vessel disease:effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension[J]. FASEB J,2013,27(10):3917-3927.
[15] Mccarthy JC,Aronovitz M,Dupont JJ,et al. Short-term administration of serelaxin produces predominantly vascular benefits in the angiotensin Ⅱ/L-NAME chronic heart failure model[J]. JACC Basic Transl Sci,2017,2(3):285-296.
[16] Bani-Sacchi T,Bigazzi M,Bani D,et al. Relaxin-induced increased coronary flow through stimulation of nitric oxide production[J]. Br J Pharmacol,1995,116(1):1589-1594.
[17] Baccari MC,Bani D. Relaxin and nitric oxide signalling[J]. Curr Protein Pept Sci,2008,9(6):638-645.
[18] Bani D,Masini E,Bello MG,et al. Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart[J]. Am J Pathol,1998,152(5):1367-1376.
[19] Valle RJ,Mauro AG,Devarakonda T,et al. Reperfusion therapy with recombinant human relaxin-2(serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism[J]. Cardiovasc Res,2017,113(6):609-619.
[20] Leo CH,Jelinic M,Gooi JH,et al. A vasoactive role for endogenous relaxin in mesenteric arteries of male mice[J]. PLoS One,2014,9(9):e107382.
[21] Stankevicius E,Dalsgaard T,Kroigaard C,et al. Opening of small and intermediate calcium-activated potassium channels induces relaxation mainly mediated by nitric-oxide release in large arteries and endothelium-derived hyperpolarizing factor in small arteries from rat[J]. J Pharmacol Exp Ther,2011,339(3):842-850.
[22] Lian X,Beer-Hammer S,Konig GM,et al. RXFP1 receptor activation by relaxin-2 induces vascular relaxation in mice via a Gαi2-protein/PI3K?/γ/nitric oxide-coupled pathway[J]. Front Physiol,2018,9:1234.
[23] Pini A,Boccalini G,Baccari MC,et al. Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2(serelaxin)[J]. J Cell Mol Med,2016,20(5):891-902.
[24] Ng HH,Leo CH,Parry LJ. Serelaxin(recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta[J]. Pharmacol Res,2016,107:220-228.
[25] Leo CH,Jelinic M,Ng HH,et al. Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin(recombinant human H2 relaxin)[J]. Br J Pharmacol,2016,173(6):1005-1017.
[26] Bischoff SJ,Schmidt M,Lehmann T,et al. Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of serelaxin in a sheep model[J]. Am J Physiol Heart Circ Physiol,2016,311(3):H613-H620.
[27] Zheng G,Cai J,Chen X,et al. Relaxin ameliorates renal fibrosis and expression of endothelial cell transition markers in rats of isoproterenol-induced heart failure[J]. Biol Pharm Bull,2017,40(7):960-966.
[28] Cai J, Chen X, Chen X, et al. Anti-fibrosis effect of relaxin and spironolactone combined on isoprenaline-induced myocardial fibrosis in rats via inhibition of endothelial-mesenchymal transition[J]. Cell Physiol Biochem,2017,41(3):1167-1178.
[29] Zhou X,Chen X,Cai JJ,et al. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway[J]. Drug Des Devel Ther,2015,9:4599-4611.
[30] Ahmad N,Wang W,Nair R,et al. Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1:induction of MMP-9 involves the PI3K, ERK, Akt and PKC-zeta pathways[J]. Mol Cell Endocrinol,2012,363(1-2):46-61.
[31]Chow BS,Chew EG,Zhao C,et al. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases:the additional involvement of iNOS[J]. PLoS One,2012,7(8):e42714.
[32] Collino M,Rogazzo M,Pini A,et al. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury[J]. J Cell Mol Med,2013,17(11):1494-1505.